Vaginitis Therapeutics Market 2019 Competitive Analysis: Lupin, Pfizer Inc, Sanofi, Teva Pharmaceutical Industries Ltd, Bausch Health, DARÉ BIOSCIENCE, INC

The new report titled "Global Vaginitis Therapeutics Market" By Types (Bacterial Vaginosis, Trichomoniasis, Vulvovaginal Candidiasis and Others), Drug Class (Anti-fungal, Anti-bacterial, Hormone and Others), Medication Type (Over-The-Counter (OTC), Prescription (Rx)), Route of Administration (Oral, Topical), End- Users (Hospitals, Specialized Gynecology Centers and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies), Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) - Industry Trends and Forecast to 2026

Global Vaginitis Therapeutics Market is expected to grow at a growing CAGR of 8.9 %in the forecast period of 2019-2026. Increase in strategic alliances between the pharmaceuticals companies and high demand of disease specific novel therapies are the key factors that fueling the market growth.

Get Sample Copy of this Report @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-vaginitis-therapeutics-market

Some of the major competitors currently working in the global vaginitis therapeutics market are Lupin, Pfizer Inc, Sanofi, Teva Pharmaceutical Industries Ltd, Bausch Health, DARÉ BIOSCIENCE, INC, Hennepin Life Sciences, LLC, Starpharma Holdings Limited, PhagoMed Biopharma GmbH, TenNor Therapeutics Ltd, Enzo Biochem Inc, Tolmar Pharmaceuticals, Inc, Perrigo Company plc and others.

Market Definition:

Vaginitis is an inflammation of the vagina or vulva that results in a thick, white, cottage cheese-like vaginal discharge that is watery and usually odorless, itching and redness of the vulva and vagina and pain with urination or sex. It usually caused by an infection, lack of estrogen hormone and among others.

Market Drivers

An ongoing clinical trial conducted by many pharmaceuticals industries is propelling the growth of this market

Increase in use of antibiotics is likely to boost the market growth

High demand of disease-specific novel treatment can also act as a market driver

The competitive scenario of the market and strategic collaborations may boost the market position

Market Restraints

Limited operating revenue opportunities for research and development of targeted therapies by many pharmaceuticals is acting as a challenging factor for the growth of this market

Low healthcare budget in some developing countries is hamper the market growth
Patent expiration of branded drugs and introduction of generics is also hinders the market growth

Segmentation: Global Vaginitis Therapeutics Market

By Types

Bacterial Vaginosis
Trichomoniasis
Vulvovaginal Candidiasis
Others

By Drug Class

Anti-fungal

Miconazole
Clotrimazole
Terconazole
Others

Anti-bacterial

Clindamycin
Ceftriaxone
Erythromycin
Others

Hormone
Others

By Medication Type

Over-The-Counter (OTC)
Prescription (Rx)

By Route of Administration

Oral
Topical

By End Users

Hospitals
Specialized Gynecology Centers
Others

By Distribution Channel

Hospital Pharmacies
Retail Pharmacies

By Geography

North America
South America
Europe
Asia-Pacific
Middle East & Africa

Download Detailed TOC @ https://www.databridgemarketresearch.com/toc/?dbmr=global-vaginitis-therapeutics-market

Key Developments in the Market:

In December 2018, DARÉ BIOSCIENCE, INC entered into an agreement with Hammock Pharmaceuticals, Inc., TriLogic Pharma LLC and MilanaPharm. Under the terms of the agreement, DARÉ BIOSCIENCE, INC acquired the global rights to MP-101 for the treatment of bacterial vaginosis (BV), as well as the rights to utilize the underlying proprietary hydrogel drug delivery technology for any vaginal or urological application in humans. The acquisition of MP-101 broaden company’s woman healthcare portfolio and advances the treatment options for patient suffering from this condition

In September 2017, Symbiomix Therapeutics a subsidiary of Lupin received approval from the FDA for Solosec (secnidazole), 5-nitroimidazole antibiotic, available in 2g oral granules for the treatment of bacterial vaginosis (BV) in adult women. The approval of Solosec provides oral treatment and represents the major advance in the treatment of these patients through targeted mode of action.

Competitive Analysis:

Global vaginitis therapeutics market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares global vaginitis therapeutics market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Reasons to Purchase this Report

Current and future of global vaginitis therapeutics market outlook in the developed and emerging markets

The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period

Regions/Countries that are expected to witness the fastest growth rates during the forecast period

The latest developments, market shares, and strategies that are employed by the major market players

Inquiry Before Buying @ https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-vaginitis-therapeutics-market

Contact:

Data Bridge Market Research
US: +1 888 387 2818
UK: +44 208 089 1725
Hong Kong: +852 8192 7475
Corporatesales@databridgemarketresearch.com

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.

This release was published on openPR.